Auflistung Nach Schlagwort "renal protection"
Anzeige der Dokumente 1-9 von 9
-
Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
(2022)For almost two decades, the management of patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) was based on the optimal glycemic and blood pressure control as well as on the adequate blockade of ... -
Hypertension in chronic kidney disease: Novel insights
(2020)Management of arterial hypertension in patients with chronic kidney disease (CKD) remains a major challenge due to its high prevalence and associations with cardiovascular disease (CVD) and CKD progression. Several clinical ... -
Immune-Related Gene Polymorphisms and Pharmacogenetic Studies in Nephrology
(2021)A large subgroup of patients with chronic kidney disease still encounter serious adverse effects and lack of responsiveness to medications, possibly because of the interindividual genetic variability in genes involved in ... -
Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model
(2020)Vancomycin and piperacillin/tazobactam are reported in clinical studies to increase acute kidney injury (AKI). However, no clinical study has demonstrated synergistic toxicity, only that serum creatinine increases. To ... -
Mechanisms for cardiorenal protection of sglt-2 inhibitors
(2021)Despite optimal treatment of diabetic kidney disease (DKD) with adequate blood pressure control and agents blocking the renin-angiotensin-system (RAS), the residual cardiorenal risk of these patients remains substantially ... -
Novel Therapeutic Strategies for Cardiorenal Protection in Patients with Type 2 Diabetes and Chronic Kidney Disease
(2022)Type 2 diabetes mellitus (T2DM) is the leading cause of end-stage kidney disease (ESKD) worldwide [1]. The development of chronic kidney disease (CKD) in patients with T2DM sub-stantially increases their risk for cardiovascular ... -
SGLT-2 inhibitors in diabetic kidney disease: What lies behind their renoprotective properties?
(2019)Background: Despite optimal management of diabetic kidney disease (DKD) with intensive glycemic control and administration of agents blocking the renin-angiotensinaldosterone-system, the residual risk for nephropathy ... -
A unifying model of glucotoxicity in human renal proximal tubular epithelial cells and the effect of the SGLT2 inhibitor dapagliflozin
(2020)Background: Glucotoxicity in renal tubular epithelial cells (RPTECs) contributes to the pathogenesis of diabetic nephropathy. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may exert their renoprotective effect by ... -
Xanthine oxidase inhibitors may prevent or slow chronic kidney disease even in the absence of hyperuricemia
(2018)[No abstract available]